BIK (BCL2 Interacting Killer) Drug Discovery Landscape & Assay Solutions
- By admin
- 07 Aug 2026
- Comments
Navigating BH3-Only Protein Biology: High-Purity Recombinant BIK Antigens, Phospho-Mutants, and Lentiviral Systems for Apoptosis Pathway Drug Discovery.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for BIK (NBK) drug discovery and BH3 profiling. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | BIK (BCL2L14) Full-Length Recombinant Protein HEK293 Expressed, C-terminal His-tag, Endotoxin <1 EU/µg, Sequence Verified |
View BIK Products |
| Antigen (Domain) | BIK BH3 Domain Peptide (aa 51-78) Synthetic / E. coli expressed, HPLC purity >95%, Theoretical MW verified |
View BIK Products |
| Antigen (Mutants) | BIK Phospho-Mutant Panel (T33A, T33D, S35A, S35D) ERK-phosphorylation site variants for stability mechanism studies |
View BIK Products |
| Gene Delivery | BIK Promise-ORF Lentivirus (CMV promoter) Full-length ORF for stable overexpression in cancer cell lines |
View BIK Products |
| Validator | BIK siRNA Set (3 unique targets) For knockdown validation in apoptosis assays |
View BIK Products |
| Reference Antibody | Anti-BIK Rabbit Recombinant mAb (C-terminal) High specificity for Western/IF validation |
View BIK Products |
| Related Target: BCL2 | Anti-apoptotic binding partner Essential for BIK co-crystalization and competition assays |
View BCL2 Products |
| Related Target: BCL2L1 (BCL-XL) | Primary anti-apoptotic binding partner of BIK; essential for competitive binding assays and resistance bypass studies | View BCL2L1 Products |
| Related Target: MCL1 | Anti-apoptotic Bcl-2 family member; high-affinity target of BIK BH3 domain; critical resistance node | View MCL1 Products |
| Related Target: BCL2L11 (BIM) | Synergistic pro-apoptotic pathway; off-target screening control | View BCL2L11 Products |
| Related Target: PMAIP1 (NOXA) | Complementary BH3 profiling marker; selective BCL-2/MCL-1 binding | View PMAIP1 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Phospho-Regulation Stability Studies (ERK-mediated turnover) | Phospho-site mutants (T33A/T33D, S35A/S35D) expressed in HEK293, Sequence Verified, High Purity (>95%) |
| BH3 Domain Folding Integrity (for BCL-2 binding) | Helical domain antigens (aa 51-78) verified by Circular Dichroism (CD) compatibility; Endotoxin Controlled |
| Cross-Species Translation (Cyno/Mouse) | Human/Mouse/Cyno BIK ortholog proteins available with >95% purity; Sequence alignment verified |
| Intracellular Target Validation | Validated siRNA included for specificity checks; Lentivirus for stable expression in hard-to-transfect lines |
| Apoptosis Pathway Specificity | BH3-only family panel (BIK, BIM, NOXA, BAD) for counter-screening; Theoretical MW match by Mass Spec |
| Quantifying binding kinetics against anti-apoptotic panel (BCL-2, BCL-XL, MCL-1) | High-purity (>95%) recombinant BH3 domains and full-length proteins strictly verified by mass spectrometry and SDS-PAGE |
| Evaluating hyperactive mutant potency (BikDD: T33D/S35D) vs Wild-type | Sequence-verified wild-type and phosphorylation-mimetic mutant proteins (T33D/S35D) available with rigorous quality checks |
| Preserving endoplasmic reticulum (ER) membrane localization in cellular assays | Full-length ORF packaged in high-titer Lentivirus Premade Particles to guarantee native intracellular anchoring |
Live BIK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (BIK/BH3 Pathway)
- ➤ Latest Venetoclax Resistance Research
- ➤ Recent Patent Filings (BH3 Mimetics)
Global Clinical Landscape & Future Outlook
The BIK pro-apoptotic axis represents a critical but historically challenging frontier in apoptosis drug discovery. While direct therapeutic targeting of intracellular BH3-only proteins remains complex, BIK has emerged as a pivotal biomarker in BH3 profiling for predictive oncology and a mechanistic target in overcoming resistance to BCL-2 inhibitors. Unlike BAD, which is restricted to BCL-2 and BCL-XL, BIK exerts a broader pro-apoptotic pull by simultaneously neutralizing BCL-2, BCL-XL, and MCL-1 at the endoplasmic reticulum membrane.
The race for BIK-modulating therapeutics is intensifying, with major players shifting focus from traditional small-molecule BCL-2 inhibitors (Venetoclax analogs) toward proteolysis-targeting chimeras (PROTACs) and stapled peptide technologies that can engage intracellular BIK. Next-generation R&D is also exploring non-viral and viral gene delivery of hyperactive BIK mutants. Notably, the constitutively active BikDD mutant (T33D/S35D) driven by tumor-specific promoters has demonstrated potent anti-tumor efficacy in refractory breast, pancreatic, and lung cancer models. As lipid nanoparticle (LNP) and mRNA delivery platforms mature, transient intra-tumoral expression of engineered BIK variants represents a highly promising frontier for overcoming venetoclax and MCL-1 inhibitor resistance.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Stapled Peptides (BH3 Mimetics) | Aileron Therapeutics, Genentech (Research) | Solid Tumors, Lymphoma | Helical BH3 Domain Antigens (Need high-purity, properly folded aa 51-78) |
| PROTACs (BIK Degraders) | Arvinas, Nurix (BCL-2 family space) | Refractory CLL, MM | Phospho-Mutant Panels (T33/S35) for stability mechanism validation |
| Small Molecule (Stabilizers) | AbbVie, AstraZeneca (Pipeline) | Venetoclax-Resistant AML | Full-Length BIK + BCL2 Co-incubation Assays (Need Human/Cyno orthologs) |
| Gene Therapy (Overexpression) | Academic & Biotech Ventures (e.g., VISA-BikDD programs) | Pancreatic Cancer, Triple-Negative Breast Cancer (TNBC) | High-Titer Lentivirus (CMV/EF1a promoters) for stable cell line construction; Intracellular expression & apoptosis induction |
| BH3 Mimetic Combination | AbbVie, Roche/Genentech | CLL, AML, RCC | Competitive binding assays (Need high-purity BIK + BCL-2 family panel) |
| Epigenetic Restoration | Oncology Biotechs | Gastric Cancer, Colorectal Cancer | Expression validation (Need anti-BIK Benchmark Ab and siRNA) |